Short interest for Amarin Corp gives investors a sense of the degree to which investors are betting on the decline of Amarin Corp's stock. Short interest data is updated every two weeks.

Amarin Corp Stock (NASDAQ:AMRN), Short Interest Report

Amarin Corp

Amarin Corp PLC is a biopharmaceutical company. It is focused on the commercialization and development of therapeutics to improve cardiovascular, or CV, health and reduce CV risk. Its commercialized product includes Vascepa.

News

Penny Stocks

Small Cap

Intraday Update

Markets

Movers

Trading Ideas

ADIL

AGFY

AMRN

ARRY

AUMN

BBWI

BCAN

BEDU

BFLY

Bakkt Holdings, Inc. Class A Common Stock

BKKT

BLUE

CMPS

COMM

CRML

CSTL

CTKB

DAVA

DUOL

ENVB

ESTA

FIGS

GRFS

GYRE

HAYW

IHRT

INDP

INSG

IONQ

IRWD

LPSN

MGNI

MIST

MRSN

NARI

NTES

NWTN

OCEA

OKTA

ORIC

PSTG

PZZA

QURE

RNLX

RVNC

SCTL

SDGR

SHLS

SIDU

SNOW

STER

STKL

SWIM

TASK

VERX

VLCN

XMTR

Shares of  Butterfly Network, Inc.  (NASDAQ: BFLY) fell sharply during Thursday’s session after the company reported mixed fourth-quarter financial results.

Why Butterfly Network Shares Are Trading Lower By 22%? Here Are Other Stocks Moving In Thursday&#39;s Mid-Day Session

Biotech

Earnings

Guidance

Health Care

General

Amarin&#39;s Q4 2023 financials: Revenues at $74.71 million, beating consensus. US net product revenue is $64.9 million, down Y/Y. CEO Patrick Holt shares operational progress, including European market signs. Amarin initiates a $50 million buyback, on track for $40 million in annual savings.

Why Is Amarin Stock Trading Lower After Q4 Earnings?

AAOI

ASPN

ATNF

BCEL

BITF

BTBT

BTCS

BTDR

CMND

ETWO

FFNW

FTFT

GBNH

INFN

LAES

LUNR

MLEC

OCTO

PLUG

RDZN

RELL

ROMA

SDIG

SGMT

SPEC

SPWR

TGAN

TTGT

UPST

WULF

Shares of TechTarget, Inc. (NASDAQ: TTGT) rose sharply during Thursday’s session after the company announced a strategic combination with Informa Tech&#39;s digital businesses.

TechTarget shares surged 14.4% to $40.34 on Thursday.

Why TechTarget Shares Are Trading Higher By Over 14%? Here Are Other Stocks Moving In Thursday&#39;s Mid-Day Session

Amarin Corporation plc - American Depositary Shares, each representing one Ordinary Share

Amarin Corp PLC

Amarin Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMRN#NASDAQ">AMRN</a>) reported quarterly losses of $(0.01) per share which beat the analyst consensus estimate of $(0.03) by 66.67 percent. This is a 150 percent decrease over earnings of $0.02 per share from the same period last year. The company reported quarterly sales of $56.519 million which missed the analyst consensus estimate of $57.045 million by 0.92 percent. This is a 34.26 percent decrease over sales of $85.975 million the same period last year.

Earnings Beats

Earnings Misses

Amarin Corp Q1 2024 Adj EPS $(0.01) Beats $(0.03) Estimate, Sales $56.519M Miss $57.045M Estimate

<h3>Gainers</h3>
<ul>
<li>Acrivon Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACRV#NASDAQ">ACRV</a>) stock rose 12.3% to $10.67 during Wednesday's after-market session. The market value of their outstanding shares is at $329.4 million. </li>
<li>Amarin Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMRN#NASDAQ">AMRN</a>) stock moved upwards by 8.12% to $0.95. The company's market cap stands at $381.2 million. </li>
<li>Universe Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UPC#NASDAQ">UPC</a>) stock rose 7.47% to $2.3. The market value of their outstanding shares is at $8.3 million. </li>
<li>China Pharma Holdings, Inc. Common Stock (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/CPHI#AMEX">CPHI</a>) shares moved upwards by 7.14% to $0.34. </li>
<li>Telesis Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TBIO#NASDAQ">TBIO</a>) shares moved upwards by 7.12% to $0.34. The company's market cap stands at $10.3 million. </li>
<li>Aesthetic Medical Intl (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AIH#NASDAQ">AIH</a>) shares moved upwards by 6.98% to $0.49. The market value of their outstanding shares is at $23.3 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Akili (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AKLI#NASDAQ">AKLI</a>) shares decreased by 11.3% to $0.22 during Wednesday's after-market session. The company's market cap stands at $17.2 million. </li>
<li>BiomX (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/PHGE#AMEX">PHGE</a>) shares fell 5.24% to $0.32. The company's market cap stands at $17.7 million. </li>
<li>OneMedNet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONMD#NASDAQ">ONMD</a>) stock fell 4.84% to $0.55. The company's market cap stands at $13.1 million. </li>
<li>Dare Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DARE#NASDAQ">DARE</a>) shares decreased by 3.68% to $0.28. The company's market cap stands at $27.7 million. </li>
<li>Mereo BioPharma Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MREO#NASDAQ">MREO</a>) stock fell 3.6% to $2.68. The company's market cap stands at $375.8 million. </li>
<li>Biomarin Pharmaceutical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMRN#NASDAQ">BMRN</a>) shares fell 3.49% to $88.02. The market value of their outstanding shares is at $16.7 billion. The company's, Q1 earnings came out today. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ACRV

AKLI

BMRN

CPHI

DARE

MREO

ONMD

PHGE

TBIO

12 Health Care Stocks Moving In Wednesday's After-Market Session

Amarin Corporation plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMRN#NASDAQ">AMRN</a>) today highlighted three data presentations at ACC.24 showcasing the mechanistic activity of Eicosapentaenoic&nbsp;acid (EPA), including the potential effects&nbsp;of EPA on endothelial cell dysfunction and&nbsp;on oxidation of samples enriched with&nbsp;Lp(a). &nbsp;
"The data presented at ACC.24 provide new evidence surrounding the mechanism of action for VASCEPA/VAZKEPA, including the effect of the compound in combination with high-intensity statin on endothelial cell function during inflammation and the compound's effect on Lp(a) levels," said R. Preston Mason, Ph.D., Brigham and Women's Hospital. "These learnings further advance understanding of how EPA and VASCEPA/VAZKEPA work to reduce cardiovascular events in at-risk patients."
The studies and their key findings are outlined below:
<a href="https://www.globenewswire.com/Tracker?data=D1yv06SPeRXPm1LDfFTlhIn4v1ywsbfHRKsg3KEWUdM_bJjV2ye5w_5l-__Sxu-Db3Y6GSWClFIEPzabM8B5a7aqSvIFvo0Ya5KnAmNfkIt3enYZL1ahMNXV10Z72O278Ef4UZHwOcybCr1iQpkcAUWW-Kf175RHfDsF_gemhZNxilA7bp1cYErOzrxANwyqt4Jt6OIoGentE0X4s4K0uxrQLASYynk9MW9TMlO9XcepBsVY2GF5zgVjloaW0ZDiFyvgdgh-JWQIGGdEkJ7s1y-4bx9W8VmkFeDcFlv1e9zyvflya99jqQvQ8oEVXyN0Zm5kX6JUhFoSEwemUvHD8tQK2OOLHkFLjkAjgzaPcumxRVmUNz5mW57qp2Ip5Q1_">Eicosapentaenoic&nbsp;acid (EPA) and a High Intensity Statin&nbsp;Enhanced Expression of Proteins for Detoxification of&nbsp;Reactive Oxygen Species during Angiotensin II Challenge in&nbsp;Endothelial Cells</a>
This analysis measured the separate and combined effects of EPA and&nbsp;rosuvastatin on expression of proteins involved in detoxification in&nbsp;vascular endothelial cells under inflammatory conditions with angiotensin II&nbsp; (Ang II).
The combination of&nbsp;EPA and rosuvastatin favorably modulated the expression of proteins related to oxidative stress and detoxification under disease-like conditions.&nbsp;These findings indicate that the&nbsp;net benefits of a high intensity statin and EPA, compared to statin alone, on&nbsp;expression of detoxification proteins during inflammation may contribute to&nbsp;reduced atherothrombotic risk in outcome trials.
<a href="https://www.globenewswire.com/Tracker?data=D1yv06SPeRXPm1LDfFTlhGKpwfwzzKo-UJWjdrrJX682o-H-uoE3r1vhxel2OjF0mj18XttQr2JcAaUEPlmIUPOhyAuqEdzFu4CDbUAIbyAX3uDYPJUYI51iqC6d7uHnIP2dzpTdUhHjC-8ySpq21_0Abdc8DQS31fiVvT1BVmWXvatHvT5VW4yIeme8IwU164H4zVUBPAO7gwg5PG9lQGaRm9IvYogNeR6nVxx7ElkOg1o7U8GerQQTp3vJCt8i7LJ5Ii0jvateA4ltpiMDBYBZ_yyNvZbqd6sEMEyXchiCXT3vUQq0gdkEFZwjknbsuYcikSorRHRQ1T5dxLUBeNwEXuywzgWeCWC-3IhgnTU=">Eicosapentaenoic&nbsp;Acid (EPA) and Rosuvastatin Modulate&nbsp;Expression of Endothelial Proteins that Regulate Function and&nbsp;Platelet Activity during Angiotensin II Stimulation&nbsp;</a>
In this analysis, investigators compared the separate and combined effects of EPA and rosuvastatin on expression of proteins that regulate platelet signaling and nitric oxide (NO) levels in human umbilical vein endothelial cells (HUVECs) subjected to angiotensin II (Ang II) stimulus.
The combination of EPA and rosuvastatin favorably modulated proteins involved in platelet degranulation and NO bioavailability in HUVECs under inflammatory conditions to a greater extent than their separate treatments. The beneficial effects of a high intensity statin and EPA on endothelial dysfunction may contribute to reduced atherothrombotic risk in outcome trials.
<a href="https://www.globenewswire.com/Tracker?data=D1yv06SPeRXPm1LDfFTlhGKpwfwzzKo-UJWjdrrJX69D4wJmgOkGikhog-PUnfmx7d9HJCnWBXAZYOnziWvlehnwT7mXQZxVeT81RiEJQww4ICdi283JtFhQgJghrC8jY_3RXSEoJ1kJNfLlxrrZeN_PLRxdrnKQlbL3OFYv6z-DYE2tiibOv_F7IzPVLsS94Nng1YFBg7ALrYatca5298gZ8V0u6msdv9KY2Q48jvWehnhADbGhbrWolLs7Wza0GM8bdI14zCYw4d_aqWUELw==">Eicosapentaenoic&nbsp;Acid (EPA) Inhibits Lipoprotein(a) [Lp(a)] Oxidation due to Scavenging Mechanisms In Vitro</a>
Elevated&nbsp;Lp(a) levels are an independent and causal risk factor for cardiovascular (CV) disease with limited treatments available. Oxidized&nbsp;Lp(a) stimulates&nbsp;foam cell formation, endothelial dysfunction, and inflammation.&nbsp;​
In this analysis, investigators tested EPA effects on oxidation of samples enriched with Lp(a) compared to the fully saturated eicosaenoic acid (EA; 20:0) and Trolox, a water-soluble analog of Vitamin E.
Investigators found that EPA inhibited oxidation of&nbsp;Lp(a) enriched plasma in a time-dependent fashion consistent with a free radical scavenging mechanism. The potent&nbsp;antioxidant actions of EPA may contribute to reduced CV events in REDUCE-IT, including among those subjects with elevated&nbsp;Lp(a).

Amarin Highlights Key Data Providing Mechanistic Insights Into Eicosapentaenoic Acid At ACC.24

Reported Saturday, New REDUCE-IT Analyses By Amarin Show That VASCEPA/VAZKEPA Benefits High-Risk Cardiovascular Disease Patient Subgroups

WIIM

Amarin shares are trading higher. The company announced it received a Decision to Grant from the European Patent Office for a new patent covering VAZKEPA that will extend VAZKEPA exclusivity eight additional years into 2039.

Amarin Received Decision To Grant From European Patent Office For New Patent Covering VAZKEPA That Will Extend VAZKEPA Exclusivity Eight Additional Years Into 2039.

-- Subgroup Analyses from REDUCE-IT&#xAE; and Mechanistic Data on Icosapent Ethyl(IPE)/Eicosapentaenoic Acid (EPA) Featured at the Meeting --&nbsp; &nbsp; &nbsp;
DUBLIN, Ireland and BRIDGEWATER, N.J., March 25, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMRN#NASDAQ">AMRN</a>) today announced that additional patient subgroup analyses from the landmark REDUCE-IT outcomes trial and mechanistic data on icosapent ethyl (IPE)/eicosapentaenoic acid (EPA) will be presented at the American College of Cardiology's Annual Scientific Session &amp; Expo, April 6 – 8, 2024 in Atlanta, GA.
"The data being featured at ACC.24 continues to support and explain the clinical utility and value of VASCEPA&#xAE;/VAZKEPA&#xAE; (icosapent ethyl), not only in the overall REDUCE IT patient population, but in the different sub-populations analyzed so far," said Nabil Abadir, MB. CH.B., SVP, Chief Medical Officer, and Head of Global Medical Affairs at Amarin "The data highlight VASCEPA/VAZKEPA's effect on reducing MACE in patients with different baseline levels of Lipoprotein(a) [Lp(a)] including among those with clinically relevant Lp(a) elevation as well as among patients with high and low LDL-C baseline levels. These data demonstrate the molecule's impact in reducing patients' residual cardiovascular event risk across these patient sub-groups regardless of their baseline Lp(a) or LDL-C levels. Additionally, the meeting provides an opportunity to highlight further evidence regarding the potential mechanistic activity of EPA in reducing cardiovascular events in at-risk patients."
"This latest research reaffirms Amarin's commitment to advancing cardiovascular care and should help further advance the medical community's understanding of the role, the value and the potential mechanism of action of VASCEPA/VAZKEPA to reduce cardiovascular events in at-risk patients globally," concluded Abadir.
Featured Amarin-supported abstracts to be presented by international academic collaborators at ACC Scientific Sessions 2024 include:
Moderated Poster Presentations
<ul>
<li><a href="https://www.abstractsonline.com/pp8/#!/10973/presentation/12162">Icosapent&nbsp;Ethyl Reduces MACE in Patients with Elevated Triglycerides and High or Low Lipoprotein(a) Concentrations: A REDUCE-IT&nbsp;Subanalysis</a> Michael&nbsp;Szarek, Deepak L. Bhatt, Elliot A. Brinton, Michael Miller, et al. –Available April 6th, 3:30-3:40 PM -Moderated Poster Theater 06</li>
<li><a href="https://www.abstractsonline.com/pp8/#!/10973/presentation/12627">Efficacy of Icosapent Ethyl for Reducing Cardiovascular Outcomes by Baseline Low Density Lipoprotein Cholesterol Level</a> Rahul Aggarwal, Deepak L. Bhatt, Philippe Gabriel Steg, Michael Miller, et al. -Available Apil 6th, 12:15-12:25 PM -Moderated Poster Theater 08</li>
<li><a href="https://www.abstractsonline.com/pp8/#!/10973/presentation/12170">Eicosapentaenoic&nbsp;Acid (EPA) Inhibits Lipoprotein(a) [Lp(a)] Oxidation due to Scavenging Mechanisms in Vitro</a> Samuel C.R. Sherratt, Peter Libby, Deepak L. Bhatt, R. Preston Mason, et al. -Available April 7th, 9:30-9:40 AM -Moderated Poster Theater 06</li>
</ul>
Poster Presentations
<ul>
<li><a href="https://www.abstractsonline.com/pp8/#!/10973/presentation/21598">Eicosapentaenoic Acid (EPA) and a High Intensity Statin Enhanced Expression of Proteins for Detoxification of Reactive Oxygen Species During Angiotensin II Challenge in Endothelial Cells</a> Samuel C.R. Sherratt, Peter Libby, Deepak L. Bhatt, R. Preston Mason, et al. -Available April 7th, 1:15-2:00 PM -Hall B4-5</li>
<li><a href="https://www.abstractsonline.com/pp8/#!/10973/presentation/21599">Eicosapentaenoic Acid and Rosuvastatin Modulate Expression of Endothelial Proteins that Regulate Function and Platelet Activity During Angiotensin II Stimulation</a> Samuel C.R. Sherratt, Peter Libby, Deepak L. Bhatt, R. Preston Mason, et al. -Available April 7th, 1:15-2:00 PM -Hall B4-5</li>
<li><a href="https://www.abstractsonline.com/pp8/">Effects of Icosapent Ethyl on Vascular Regenerative Cells in Individuals with Elevated Triglycerides: Insights From the IPE-Prevention Cardiolink-14 Trial</a> Ehab Bakbak, Aishwarya Krishnaraj, Deepak L. Bhatt, Brady Park, et al. –Available April 8th, 12:45-1:30 PM - Hall B4-5</li>
</ul>

Events

Amarin Announces Research Evaluating Benefits Of VASCEPA/VAZKEPA To Be Presented At The American College Of Cardiology's Annual Scientific Session & Expo

Shares of Butterfly Network, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/bfly#NASDAQ">BFLY</a>) fell sharply during Thursday&rsquo;s session after the company reported mixed fourth-quarter financial results.
Butterfly Network posted GAAP loss of 21 cents per share versus market estimates for a loss of 14 cents per share. The company&rsquo;s quarterly sales came in at sales came in $16.52 million versus estimates of $15.35 million.
Butterfly Network shares dipped 21.7% to $1.1588 on Thursday.
Here are some other stocks moving in today&#39;s mid-day session.
<h3>Gainers</h3>
<ul>
<li>Enveric Biosciences, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/envb#NASDAQ">ENVB</a>) gained 177.1% to $2.30 after the company announced it has signed three non-binding term sheets with an undisclosed biotechnology company to pursue the out-licensing of compounds.</li>
<li>Societal CDMO, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/sctl#NASDAQ">SCTL</a>) shares climbed 132.7% to $1.07 as the company agreed to be acquired by CoreRx, Inc.</li>
<li>Volcon, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/vlcn#NASDAQ">VLCN</a>) gained 55.4% to $1.8802 after surging around 39% on Wednesday.</li>
<li>Sidus Space, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/sidu#NASDAQ">SIDU</a>) climbed 39.7% to $7.78.</li>
<li>Ocean Biomedical, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ocea#NASDAQ">OCEA</a>) gained 36.4% to $2.1008. Ocean Biomedical announced joint venture partner, Virion Therapeutics to present clinical study data at 2024 APASL Global Liver Meeting.</li>
<li>Inseego Corp. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/insg#NASDAQ">INSG</a>) rose 34.5% to $3.00.</li>
<li>Vertex, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/verx#NASDAQ">VERX</a>) jumped 29.8% to $32.97 after the company reported better-than-expected fourth-quarter results and issued strong FY24 guidance.</li>
<li>iHeartMedia, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ihrt#NASDAQ">IHRT</a>) rose 29.1% to $2.93 following fourth-quarter results.</li>
<li>Agrify Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/agfy#NASDAQ">AGFY</a>) gained 27% to $0.6161. Agrify announced a $3.4 million sales order from New Jersey woman-owned business HarvestWorks Farm.</li>
<li>Renalytix Plc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/rnlx#NASDAQ">RNLX</a>) climbed 26.5% to $1.05 after the company announced that effective Mar. 1, the US approved adding the company&#39;s kidneyintelX.dkd to its 10-year Governmentwide Acquisition Contract.</li>
<li>Tutor Perini Corporation (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/tpc#NYSE">TPC</a>) gained 26% to $11.64 following fourth-quarter results.</li>
<li>Bright Scholar Education Holdings Limited (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/bedu#NYSE">BEDU</a>) gained 25.3% to $2.3178.</li>
<li>C3.ai, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/ai#NYSE">AI</a>) shares rose 24.6% to $37.00 after the company reported better-than-expected third-quarter financial results.</li>
<li>Sterling Check Corp. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ster#NASDAQ">STER</a>) jumped 24.6% to $15.49 after the company agreed to be acquired by First Advantage for approximately $2.2 billion, including outstanding debt.</li>
<li>Adial Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/adil#NASDAQ">ADIL</a>) gained 24% to $2.00. Adial Pharmaceuticals was awarded a new patent covering AD04 for the potential treatment of opioid use disorder.</li>
<li>Revance Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/rvnc#NASDAQ">RVNC</a>) jumped 24% to $7.02 after the company reported better-than-expected quarterly financial results.</li>
<li>Latham Group, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/swim#NASDAQ">SWIM</a>) climbed 22.8% to $3.36.</li>
<li>Avidity Biosciences, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/rna#NASDAQ">RNA</a>) jumped 22.5% to $18.70. Avidity Biosciences announced an oversubscribed $400 million private placement.</li>
<li>Pure Storage, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/pstg#NYSE">PSTG</a>) rose 21.9% to $51.35 after the company reported better-than-expected fourth-quarter financial results and issued first-quarter revenue guidance above estimates. Also, UBS maintained a Neutral rating on the stock and raised its price target from $38 to $44.</li>
<li>Duolingo, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/duol#NASDAQ">DUOL</a>) gained 21.6% to $237.82 after the company reported better-than-expected fourth-quarter financial results and issued strong guidance.</li>
<li>Okta, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/okta#NASDAQ">OKTA</a>) shares rose 19.8% to $104.55 after the company reported better-than-expected fourth-quarter financial results and issued strong guidance.</li>
<li>Mersana Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mrsn#NASDAQ">MRSN</a>) gained 19.5% to $5.80 after the company reported fourth-quarter financial results.</li>
<li>Establishment Labs Holdings Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/esta#NASDAQ">ESTA</a>) rose 17.8% to $45.31 after the company reported better-than-expected fourth-quarter financial results.</li>
<li>Montrose Environmental Group, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/meg#NYSE">MEG</a>) gained 16.7% to $38.52 following quarterly results.</li>
<li>ORIC Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/oric#NASDAQ">ORIC</a>) climbed 16.1% to $13.65.</li>
<li>SunOpta Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/stkl#NASDAQ">STKL</a>) rose 15% to $6.91 following strong quarterly results.</li>
<li>TaskUs, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/task#NASDAQ">TASK</a>) gained 14.4% to $14.17 following upbeat quarterly results.</li>
<li>Magnite, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mgni#NASDAQ">MGNI</a>) rose 13.8% to $11.93 following strong quarterly results.</li>
<li>Indaptus Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/indp#NASDAQ">INDP</a>) rose 13.8% to $2.23.</li>
<li>Hayward Holdings, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/hayw#NASDAQ">HAYW</a>) gained 13.7% to $14.88 following upbeat results.</li>
<li>Hormel Foods Corporation (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/hrl#NYSE">HRL</a>) rose 12.8% to $34.81 after the company reported better-than-expected first-quarter earnings and reaffirmed FY24 outlook.</li>
<li>Nxu, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nxu#NASDAQ">NXU</a>) shares rose 9.2% to $0.7750. Nxu said it fully regained compliance with Nasdaq&#39;s continued listing requirements.</li>
<li>NFT Limited (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/mi#NYSE">MI</a>) shares jumped 7.9% to $0.2374.</li>
<li>Sprinklr, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/cxm#NYSE">CXM</a>) gained 7.9% to $13.56. Sprinklr will replace Veradigm in S&amp;P SmallCap 600 effective prior to opening of trading on March 4, 2024.</li>
<li>Papa John&#39;s International, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/pzza#NASDAQ">PZZA</a>) climbed 6.8% to $74.89 following strong quarterly earnings.</li>
</ul>
<h3>Losers</h3>
<ul>
<li>J-Long Group Limited (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/jl#NYSE">JL</a>) fell 46.3% to $6.86. J-Long Group declared a special cash dividend in aggregate amount of $6 million.</li>
<li>Golden Minerals Company (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/aumn#NYSE">AUMN</a>) dipped 40.4% to $0.3163. Golden Minerals announced that it has elected to stop operations at its Velarde&ntilde;a Properties, located in Durango State, Mexico.</li>
<li>LivePerson, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/lpsn#NASDAQ">LPSN</a>) shares declined 40% to $1.43 following fourth-quarter financial results.</li>
<li>NWTN Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nwtn#NASDAQ">NWTN</a>) fell 40% to $2.99.</li>
<li>Endava plc (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/dava#NYSE">DAVA</a>) fell 40% to $38.31 following second-quarter earnings.</li>
<li>Kineta, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ka#NASDAQ">KA</a>) fell 39.7% to $1.3801 as the company announced intention to explore strategic alternatives.</li>
<li>Ironwood Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/irwd#NASDAQ">IRWD</a>) fell 39% to $9.23 after the company&#39;s Phase 3 trial of once-weekly subcutaneous apraglutide did not meet two out of four key secondary endpoints.</li>
<li>Xometry, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/xmtr#NASDAQ">XMTR</a>) fell 37.4% to $18.84 after the company reported fiscal fourth-quarter results and issued first-quarter guidance below estimates and disclosed a CFO transition.</li>
<li>Grifols, S.A. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/grfs#NYSE">GRFS</a>) fell 36.7% to $5.91.</li>
<li>The Chemours Company (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/cc#NYSE">CC</a>) shares declined 33.7% to $19.05. Chemours Company named Denise Dignam as the interim CEO and Matt Abbott as the interim CFO. The company also issued preliminary 2023 results.</li>
<li>Bakkt Holdings, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/bkkt#NASDAQ">BKKT</a>) fell 33.4% to $0.6792 after the company announced two securities purchase agreements.</li>
<li>CommScope Holding Company, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/comm#NASDAQ">COMM</a>) dipped 30% to $1.2950 after the company reported financial fourth-quarter results below estimates.</li>
<li>Critical Metals Corp. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/crml#NASDAQ">CRML</a>) fell 25.2% to $11.43.</li>
<li>Gyre Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/gyre#NASDAQ">GYRE</a>) dropped 22% to $19.34.</li>
<li>Lotus Technology Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/lot#NASDAQ">LOT</a>) fell 21.8% to $7.71.</li>
<li>BYND Cannasoft Enterprises Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/bcan#NASDAQ">BCAN</a>) shares fell 20.2% to $0.1621. BYND Cannasoft is entering into production agreements for its EZ-G Device.</li>
<li>Snowflake Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/snow#NYSE">SNOW</a>) shares tumbled 20.1% to $183.81. Snowflake reported upbeat earnings for its fourth quarter. The company said CEO Frank Slootman has decided to retire from his role as CEO but will continue to serve as chairman of the board. Sridhar Ramaswamy has been appointed as CEO and a member of the board, effective immediately.</li>
<li>Schr&ouml;dinger, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/sdgr#NASDAQ">SDGR</a>) shares declined 19.9% to $25.12 after the company reported mixed fourth-quarter financial results.</li>
<li>Castle Biosciences, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cstl#NASDAQ">CSTL</a>) fell 18.7% to $19.83 following fourth-quarter financial results.</li>
<li>bluebird bio, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/blue#NASDAQ">BLUE</a>) fell 18.2% to $1.3750.</li>
<li>Inari Medical, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nari#NASDAQ">NARI</a>) shares fell 18.1% to $47.50 after posting a loss for the fourth quarter.</li>
<li>WW International, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ww#NASDAQ">WW</a>) fell 17.9% to $3.1350 after the company reported fourth-quarter financial results and announced that director Oprah Winfrey has decided not to stand for re-election at the company&#39;s upcoming annual meeting of shareholders.</li>
<li>uniQure N.V. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/qure#NASDAQ">QURE</a>) fell 16.7% to $5.57. Goldman Sachs analyst Salveen Richter downgraded uniQure from Buy to Neutral and lowered the price target from $63 to $8.</li>
<li>Amarin Corporation plc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/amrn#NASDAQ">AMRN</a>) fell 16.7% to $1.09 following quarterly results.</li>
<li>DoubleVerify Holdings, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/dv#NYSE">DV</a>) declined 16.6% to $32.71 after the company reported fourth quarter financial results.</li>
<li>Shoals Technologies Group, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/shls#NASDAQ">SHLS</a>) shares dipped 16.3% to $12.89 after the company reported worse-than-expected fourth-quarter financial results and issued FY24 revenue guidance below estimates.</li>
<li>Milestone Pharmaceuticals Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mist#NASDAQ">MIST</a>) shares fell 16% to $1.7897 after announcing a proposed public offering of common shares and pre-funded warrants.</li>
<li>COMPASS Pathways plc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cmps#NASDAQ">CMPS</a>) fell 16% to $10.40 following a wider-than-expected quarterly loss.</li>
<li>FIGS, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/figs#NYSE">FIGS</a>) shares fell 15.4% to $5.10 after the company reported mixed quarterly financial results.</li>
<li>The Lion Electric Company (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/lev#NYSE">LEV</a>) dipped 12.6% to $1.46 following fourth quarter financial results.</li>
<li>Cytek Biosciences, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ctkb#NASDAQ">CTKB</a>) fell 12.2% to $7.67 following fourth quarter financial results.</li>
<li>AMC Entertainment Holdings, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/amc#NYSE">AMC</a>) shares fell 11.1% to $4.4350 following quarterly results.</li>
<li>Titan International, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/twi#NYSE">TWI</a>) fell 10% to $12.73 following weak sales.</li>
<li>IonQ, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/ionq#NYSE">IONQ</a>) shares declined 7.2% to $10.45 after the company reported mixed fourth quarter financial results.</li>
<li>Array Technologies, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/arry#NASDAQ">ARRY</a>) fell 5.8% to $13.27.</li>
<li>Bath &amp; Body Works, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/bbwi#NASDAQ">BBWI</a>) fell 5.2% to $45.80 after the company reported fourth-quarter earnings and issued worse-than-expected FY24 outlook. It also authorized $500 million stock buyback.</li>
<li>NetEase, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ntes#NASDAQ">NTES</a>) shares fell 3.7% to $108.03 after the company reported financial fourth-quarter results below estimates.</li>
</ul>
&nbsp;
Now Read This: <a href="https://www.benzinga.com/news/24/02/37390717/nvidia-to-rally-around-27-here-are-10-top-analyst-forecasts-for-thursday"> NVIDIA To Rally Around 27%? Here Are 10 Top Analyst Forecasts For Thursday</a>

Why Butterfly Network Shares Are Trading Lower By 22%? Here Are Other Stocks Moving In Thursday's Mid-Day Session

Amarin Corporation Plc&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMRN#NASDAQ">AMRN</a>) reported fourth-quarter 2023 revenues of $74.71 million, down from $90.2 million, beating the&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">consensus of $63.81 million</a>.
The 17% Y/Y decline in revenues was driven primarily by a decrease in the volume of VASCEPA sales to Amarin&#8217;s customers in the United States, which were adversely impacted by generic&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/24/02/g37388829/amarin-reports-fourth-quarter-and-full-year-2023-financial-results-and-provides-business-update" rel="noreferrer noopener">availability in the United States</a>.&nbsp;
U.S. net product revenue was $64.9 million, down $88 million a year ago. European net product revenue was $1.5 million, and the Rest of the World was $4.2 million, primarily from supply shipments to partner Edding.
The company almost reported a break-even, beating the consensus loss of $(0.03), but down from income of $0.02 a year ago.
&#8220;Our team is delivering operational momentum in the business. As previously announced in January, in Europe, we are showing early signs of progress, particularly in Spain and the U.K.; our U.S. business is continuing its IPE market leadership; and our Rest of World partners are advancing plans to maximize patient uptake,&#8221; said Patrick Holt, President &amp; CEO of Amarin.&nbsp;
Buyback:&nbsp;Amarin initiated a shareholder approval process to execute a share repurchase program of up to $50 million by the end of the second quarter 2024.
Outlook:&nbsp;Amarin continues to progress in reducing operating expenses and managing its cash position. It is on track to deliver $40 million of annual savings based on the reduction in force announced in July 2023.&nbsp;
With the recent cash preservation initiatives, Amarin reiterates that current cash, investments, and other assets are adequate to support continued operations, including the share repurchase program.&nbsp;
&#8220;We will continue to focus on cash preservation and prudently invest in the right opportunities which are value additive,&#8221; the company said.
Price Action:&nbsp;AMRN shares are down 17.8% at $1.09 on the last check Thursday.

Amarin Continues To Make Progress On Reducing Operating Expenses And Managing Its Cash Position

Buybacks

Amarin Says Initiated Shareholder Approval Process To Execute Share Repurchase Program Of Up To $50M By End Of Q2 2024

Amarin Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMRN#NASDAQ">AMRN</a>) reported quarterly Adj earnings of $0.00 per share which beat the analyst consensus estimate of $(0.03) by 103.33 percent. This is a 95 percent decrease over earnings of $0.02 per share from the same period last year. The company reported quarterly sales of $74.71 million which beat the analyst consensus estimate of $63.81 million by 17.09 percent. This is a 17.21 percent decrease over sales of $90.25 million the same period last year.

Amarin Corp Q4 Adj EPS $0.00 Beats $(0.03) Estimate, Sales $74.71M Beat $63.81M Estimate

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Amarin Corp Stock (NASDAQ:AMRN), Short Interest Report

People Also Watch